Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SLXN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSilexion executes 1-for-10 reverse stock split, warrant exercise price jumps to $15,525
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
Reverse split effective May 28, 2026: every 10 existing shares consolidated into 1 share, reducing outstanding share count by 90% while proportionally increasing per-share price. Par value increased from $0.0135 to $0.135 per share.
Item 3.03 verify on EDGAR → -
high
Outstanding warrants adjusted to maintain economic equivalence: exercise price increased ten-fold to $15,525.00 per post-split share. Each warrant now represents 1/10th of a share instead of a full share.
Item 3.03 verify on EDGAR → -
medium
Fractional warrant shares will be rounded up to nearest whole share at broker level, but holders must pay full exercise price for that whole share, creating small economic benefit for fractional positions.
Item 3.03 verify on EDGAR → -
low
Shares began trading on post-split basis May 29, 2026 under existing ticker SLXN with new CUSIP G1281K148. Warrant ticker SLXNW and CUSIP unchanged.
Item 3.03 verify on EDGAR →
Summary
Silexion Therapeutics completed a 1-for-10 reverse stock split after market close on May 28, 2026, following shareholder approval. The action consolidated every 10 existing shares into 1 share, reducing the outstanding share count by 90% while proportionally increasing the per-share price. The company's authorized shares decreased to 5.9 million with par value rising from $0.0135 to $0.135 per share.
Outstanding warrants were adjusted to maintain economic equivalence, with exercise prices jumping ten-fold to $15,525.00 per post-split share. Reverse splits are typically executed to meet minimum share price requirements for continued exchange listing or to improve perceived market standing.
For Silexion warrant holders (ticker SLXNW), the dramatically higher $15,525 exercise price may make these warrants effectively worthless unless the stock price increases substantially. Retail investors should monitor whether the company provides guidance on why the split was necessary and watch for any subsequent dilutive financing that could pressure the post-split share price. The next quarterly filing should reveal the actual post-split share count and any changes in the shareholder base.
Section-by-Section Diff
Event · Item 3.03 — Material Modification to Rights of Security Holders
Silexion disclosed a material modification to shareholder rights in connection with a previously-announced 1-for-10 reverse share split.
Added in current filing · verify on EDGAR →
In connection with its previously-announced 1-for-10 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the “Reverse Share Split”)
The company filed an 8-K under Item 3.03 to disclose a material modification to the rights of security holders related to a 1-for-10 reverse share split. This means every 10 existing shares will be consolidated into 1 share, reducing the total share count by 90% while proportionally increasing the per-share price. The filing appears incomplete as it cuts off mid-sentence.
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Silexion executed a 1-for-10 reverse stock split, adjusting warrant exercise prices to $15,525.00 per share and reducing shares outstanding proportionately.
Added in current filing · verify on EDGAR →
On May 28, 2026, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company’s Amended and Restated Memorandum of Association (the “Memorandum Amendment”). As a result of that filing, the authorized share capital of the Company remains at $796,500, now consisting of 5,900,000 ordinary shares, and the par value of the ordinary shares has increased from $0.0135 per share to $0.135 per share. In addition, the number of issued and outstanding ordinary shares has decreased at a ratio of 1-for-10.
The company completed a 1-for-10 reverse stock split effective after market close on May 28, 2026. Every 10 pre-split shares became 1 post-split share, reducing the total outstanding share count proportionately. The par value per share increased from $0.0135 to $0.135, and authorized shares decreased to 5,900,000 while total authorized capital remained $796,500.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Reverse Share Split became effective after the close of business on May 28, 2026, and the Company’s ordinary shares will begin trading on a Reverse Share Split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol “SLXN” at the market open on May 29, 2026. After the Reverse Share Split, the trading symbol for the Company’s ordinary shares will continue to be “SLXN.” The new CUSIP number for the Company’s ordinary shares is G1281K148.
The ordinary shares began trading on a post-split basis on May 29, 2026, under the same ticker symbol SLXN but with a new CUSIP number G1281K148. The warrant ticker SLXNW and warrant CUSIP G1281K 114 remain unchanged despite the warrant adjustments.
Event · Item 8.01 — Other Events
8-K cross-references Items 3.03 and 5.03 without disclosing substantive details in Item 8.01.
Added in current filing · verify on EDGAR →
The information set forth in Items 3.03 and 5.03 is hereby incorporated by reference into this Item 8.01.
The 8-K discloses an Item 8.01 Other Events entry that incorporates by reference information from Items 3.03 (Material Modification to Rights of Security Holders) and 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year). Without the full filing text for those items, the specific event cannot be determined from this excerpt alone.
Event · Item 9.01 — Financial Statements and Exhibits
Silexion filed a Memorandum Amendment and Warrant Adjustment Notice, both dated May 28-29, 2026.
Added in current filing · verify on EDGAR →
3.1 Memorandum Amendment, dated May 28, 2026.
The company filed a Memorandum Amendment dated May 28, 2026. The 8-K does not provide details on what the amendment modifies, but memorandum amendments typically relate to changes in corporate charter or organizational documents. Investors should review the full exhibit to understand the specific changes made.
Added in current filing · verify on EDGAR →
4.1 Warrant Adjustment Notice, dated May 29, 2026.
The company issued a Warrant Adjustment Notice dated May 29, 2026. Warrant adjustments typically occur due to corporate actions such as stock splits, dividends, or recapitalizations that affect the terms of outstanding warrants. The specific adjustment terms are not disclosed in the 8-K body and would require reviewing the full exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify